Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer

Clinical Therapeutics

Volumn 31, Issue PART. 2, 2009, Pages 2332-2348

  Tevaarwerk, Amye J ^a   Kolesar, Jill M ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

dual tyrosine kinase inhibitor; EGFR; ErbB1; ErbB2; GW572016; HER2; lapatinib; Tykerb

Indexed keywords

CAPECITABINE; CARBAMAZEPINE; CARBOPLATIN; CYTOCHROME P450 3A4; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; KETOCONAZOLE; LAPATINIB; LETROZOLE; MIDAZOLAM; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; BILE DUCT CANCER; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRY SKIN; DYSPEPSIA; DYSPNEA; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATIGUE; FEVER; FOOD; FOOD DRUG INTERACTION; GALLBLADDER CANCER; GRAPE JUICE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEADACHE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERSENSITIVITY; KIDNEY CANCER; LEUKOPENIA; LIVER CANCER; LOADING DRUG DOSE; LUNG CANCER; MACULOPAPULAR RASH; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEAKNESS;

BREAST NEOPLASMS; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 74549210351     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.029     Document Type: Article

References (74)

1. Citri A., Skaria K.B., and Yarden Y. The deaf and the dumb: The biology of ErbB-2 and ErbB-3. Exp Cell Res. 284 (2003) 54-65
2. Graus-Porta D., Beerli R.R., Daly J.M., and Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16 (1997) 1647-1655
3. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 19 (2000) 3159-3167
4. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2 (2001) 127-137
5. Huang G.C., Hobbs S., Walton M., and Epstein R.J. Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br J Cancer 86 (2002) 1104-1109
6. Moyer J.D., Barbacci E.G., Iwata K.K., et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57 (1997) 4838-4848
7. Hirata A., Ogawa S., Kometani T., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62 (2002) 2554-2560
8. Wakeling A.E., Guy S.P., Woodburn J.R., et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62 (2002) 5749-5754
9. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
10. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor- related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19 (1995) 183-232
11. Jannot C.B., Beerli R.R., Mason S., et al. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 13 (1996) 275-282
12. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin. 57 (2007) 43-66
13. Singer C.F., Köstler W.J., and Hudelist G. Predicting the efficacy of trastuzumabbased therapy in breast cancer: Current standards and future strategies. Biochim Biophys Acta 1786 (2008) 105-113
14. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
15. Tripathy D., Slamon D.J., Cobleigh M., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 22 (2004) 1063-1070
16. Montemurro F., Donadio M., Clavarezza M., et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11 (2006) 318-324
17. Wood E.R., Truesdale A.T., McDonald O.B., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64 (2004) 6652-6659
18. Cockerill S., Stubberfield C., Stables J., et al. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 11 (2001) 1401-1405
19. Tykerb (lapatinib) [package insert] (2007), Glaxo-SmithKline, Research Triangle Park, NC
20. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [published correction appears in N Engl J Med. 2007;356:1487]. N Engl J Med. 355 (2006) 2733-2743
21. Owens M.A., Horten B.C., and Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5 (2004) 63-69
22. Tsuda H. HER-2 (c-erbB-2) test update: Present status and problems. Breast Cancer 13 (2006) 236-248
23. Stamos J., Sliwkowski M.X., and Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 277 (2002) 46265-46272
24. Spector N.L., Xia W., Burris III H., et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 23 (2005) 2502-2512
25. Rusnak D.W., Lackey K., Affleck K., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 1 (2001) 85-94
26. Rusnak D.W., Affleck K., Cockerill S.G., et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res. 61 (2001) 7196-7203
27. Xia W., Mullin R.J., Keith B.R., et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21 (2002) 6255-6263
28. Bence A.K., Anderson E.B., Halepota M.A., et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23 (2005) 39-49
29. Burris H.A., Taylor C., Jones S., et al. A phase I study of GW572016 in patients with solid tumors. Proc Am Soc Clin Oncol. 22 (2003) 258 Abstract 994
30. Burris III H.A., Hurwitz H.I., Dees E.C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 23 (2005) 5305-5313
31. Ratain M.J., and Cohen E.E. The value meal: How to save $1,700 per month or more on lapatinib. J Clin Oncol. 25 (2007) 3397-3398
32. Moy B., and Goss P.E. Lapatinibassociated toxicity and practical management recommendations. Oncologist 12 (2007) 756-765
33. Chu Q.S., Schwartz G., de Bono J., et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol. 25 (2007) 3753-3758
34. Siegel-Lakhai W.S., Beijnen J.H., Vervenne W.L., et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res. 13 (2007) 4495-4502
35. Storniolo A.M., Pegram M.D., Overmoyer B., et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 26 (2008) 3317-3323
36. Midgley R.S., Kerr D.J., Flaherty K.T., et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol. 18 (2007) 2025-2029
37. Mathijssen R.H., van Alphen R.J., Verweij J., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 7 (2001) 2182-2194
38. Reddy N., Cohen R., and Whitehead B. A phase I, open-label, three period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients. Clin Pharmcacol Ther. 81 Suppl (2007) S16-S17 Abstract PI-15
39. Koch K.M., Reddy N.J., Cohen R.B., et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 275 (2009) 1191-1196
40. Kelly H., Graham M., Humes E., et al. Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin Breast Cancer 7 (2006) 339-341
41. Versola M., Burris H.A., Jones S.F., et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol. 22 (2004) Abstract 3047
42. Minami H., Nakagawa K., Kawada K., et al. A phase I study of GW572016 in patients with solid tumors. J Clin Oncol. 22 Suppl 14 (2004) Abstract 3048
43. Budman D.R., Soong R., Calabro A., et al. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. Anticancer Drugs. 17 (2006) 921-928
44. Crown J.P., Burris H.A., Jones S., et al. Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). J Clin Oncol. 25 Suppl 18 (2007) Abstract 1027
45. Kimball K.J., Numnum T.M., Estes J.M., et al. A phase I trial of lapatinib in combination with carboplatin in patients with platinum sensitive recurrent epithelial ovarian cancer. J Clin Oncol. 25 (2007) 14106a
46. Cianfrocca M.E., Rosen S.T., von Roenn J.H., et al. A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): First evaluation of an anthracycline and lapatinib combination in the treatment of MBC. J Clin Oncol. 25 Suppl 18S (2007) 1079
47. LoRusso P.M., Jones S.F., Koch K.M., et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol. 26 (2008) 3051-3056
48. Kimball K.J., Numnum T.M., Kirby T.O., et al. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol. 111 (2008) 95-101
49. Chu Q.S., Cianfrocca M.E., Goldstein L.J., et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res. 14 (2008) 4484-4490
50. Safran H., Miner T., Resnick M., et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: A phase I study for advanced pancreatico-biliary cancer. Am J Clin Oncol. 31 (2008) 140-144
51. Burstein H.J., Storniolo A.M., Franco S., et al. A phase II study of lapatinib monotherapy in chemotherapyrefractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 19 (2008) 1068-1074
52. Johnston S., Trudeau M., Kaufman B., et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. 26 (2008) 1066-1072
53. Gomez H.L., Chavez M.A., Doval D.C., et al. Investigation of tumor biomarkers as response predictors in monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer. J Clin Oncol. 25 Suppl (2007) 580s Abstract 10562
54. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat. 112 (2008) 533-543
55. Gabos Z., Sinha R., Hanson J., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 24 (2006) 5658-5663
56. Lin N.U., Bellon J.R., and Winer E.P. CNS metastases in breast cancer. J Clin Oncol. 22 (2004) 3608-3617
57. Gril B., Palmieri D., Bronder J.L., et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 100 (2008) 1092-1103
58. Lin N.U., Carey L.A., Liu M.C., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 26 (2008) 1993-1999
59. Lin N.U., Diéras V., Paul D., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 15 (2009) 1452-1459
60. Chang S., Parker S.L., Pham T., et al. Inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 82 (1998) 2366-2372
61. Low J.A., Berman A.W., Steinberg S.M., et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 22 (2004) 4067-4074
62. Jones S.F., Hainsworth J.D., Spigel D.R., et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF100009). J Clin Oncol. 22 Suppl 14 (2004) Abstract 2083
63. Kaufman B., Trudeau M., Awada A., et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: Final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol. 10 (2009) 581-588
64. Yamauchi H., O'Neill A., Gelman R., et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 15 (1997) 2518-2525
65. Esteva F.J., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 20 (2002) 1800-1808
66. Chang J.C., Li X., Creighton C., et al. Decrease in tumorigenic breast cancer stem cells-final results of a neoadjuvant trial in primary breast cancer patients. Presented at: 6th European Breast Cancer Conference. Berlin, Germany (April 15-19, 2008) Abstract 204
67. Agulnik M., Cohen E.W., Cohen R.B., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 25 (2007) 3978-3984
68. Perez E.A., Byrne J.A., Hammond I.W., et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol. 24 Suppl 18 (2006) Abstract 583
69. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol. 26 (2008) 1231-1238
70. Red Book 2009: Pharmacy's Fundamental Reference. 113th ed. (2009), Thomson Reuters, Montvale, NJ
71. Di Leo A., Gomez H.L., Aziz Z., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 26 (2008) 5544-5552
72. Press M.F., Finn R.S., Di Leo A., et al. Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer. J Clin Oncol. 26 Suppl (2008) Abstract 1007
73. Carey L.A., Mayer E., Marcom P.K., et al. TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast. Breast Cancer Res Treat. 106 Suppl 1 (2007) S32 Abstract 307
74. Smaill J.B., Rewcastle G.W., Loo J.A., et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d] pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 43 (2000) 1380-1397